HIV and AIDS affect over 30 million people worldwide, and diarrhea affects 28–60% of HIV-positive patients. Patients who have low CD4 counts (less than 350) are highly susceptible to a range of opportunistic infections. Approximately 50% of patients present with an infectious etiology. HIV/AIDS patients are susceptible to bacterial and parasitic causes of diarrhea – cryptosporidiosis being one of the most difficult to treat. Patients should be counseled that ensuring compliance with their protease inhibitors is key in treating their diarrhea.
KeywordsDiarrhea Dehydration Abdominal pain Antibiotics HIV AIDS Cryptosporidiosis Antiretroviral therapy
- 2.Nwachukwu CE, Okebe JU. Antimotility agents for chronic diarrhoea in people with HIV/AIDS. Cochrane Database Syst Rev. 2008;4:CD005644.Google Scholar
- 5.Silverberg MJ, Gore ME, French AL, Gandhi M, Glebsy MJ, Kovacs A, et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the women’s interagency HIV Study. Clin Infect Dis. 2004;5(1):19–24.Google Scholar
- 6.Moyle GJ, Youle M, Higgs C, Monaghan J, Prince W, Chapman S, et al. Safety, pharmacokinetics and antiretroviral activity of the poten, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and an extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol. 1998;38:736–43.CrossRefGoogle Scholar
- 15.Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev. 2007;1:CD004932.Google Scholar